Furthermore, targeting intron 2 would allow replacement of most of the coding region of the CTNNB1 transcript, making this approach widely applicable to CTNNB1 syndrome-associated mutations, which are spread across the entire gene. The gene discussed is CTNNB1; the disease is severe intellectual disability-progressive spastic diplegia syndrome.